top of page

Epinn®

Next generation Tumor classification

Rapid tumour classification to assist the pathologist during diagnosis, shortening the timeline from 1 week to <90 minutes! Which enables rapid decision-making for the clinicians, and makes it possible to classify tumours during surgery.  Epinn enables AI-powered methylation analyses across ONT, Illumina, and bisulfite sequencing workflows.

Advantages of Epinn®

Epinn allows you to run state-of-the-art tumor classification and copy number analysis, no advanced skills required.

More advantages:

  • Local: no sample data leaves your machine. Giving you full control over your data.

  • Secure: Prioritizes data security.

  • Real-timeGet feedback about the classification at every single step of the process

  • Fast: Epinn runs multithreaded on your machine.

  • AccurateUse the latests models with the highest accuracy.

  • IntuitiveUser-friendly interface designed for ease of use.

Current models

bubbles

More in the works

We are hard at work to expand!

Status

cells

Epinn-OSCC

Classifing oral squamous cell carcinoma samples based on methylation patterns.

Status

drawing of a brain

Epinn-CNS

Our improved version of sturgeon to classifiy central nerveous system tumor biopsies.

Status

Sturgeon fish

Sturgeon

The original, Nature published, Metylation based predicition model.

Status

In the Media

Nature

October 2023

Ultra-fast deep-learned CNS tumour classification during surgery

Sturgeon

Nat Geo

October 2024

Meet Sturgeon, the AI tool that helps doctors identify brain tumors faster than ever

Sturgeon

Oncode Institute

may 2026

Cyclomics secures an exclusive worldwide license from Oncode to Sturgeon software, technology, and IP, enhancing its Epinn platform for rapid DNA methylation–based cancer classification

Sturgeon

Oncode Institute

April 2025

Oncode Investigator Jeroen de Ridder & Cyclomics receive Health~Holland PPP subsidy to continue developing brain tumor classifier

More in the works

bottom of page